Exane Derivatives’s Corteva CTVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$650 Sell
12
-2,725
-100% -$158K ﹤0.01% 548
2022
Q1
$157K Sell
2,737
-200
-7% -$10.2K 0.04% 389
2021
Q4
$139K Buy
2,937
+816
+38% +$37.2K 0.03% 404
2021
Q3
$89.2K Sell
2,121
-4,991
-70% -$216K 0.02% 536
2021
Q2
$306K Buy
+7,112
New +$329K 0.07% 284

Other funds holding CTVA

Exane Derivatives's CTVA Position: Q2 2022 in Review

Exane Derivatives reduced its Corteva (CTVA) stake by 100% in Q2 2022, selling an estimated $158K and leaving 12 shares worth $650. The position accounts for ﹤0.01% of the portfolio, ranked #548.

Exane Derivatives first reported a position in CTVA in Q2 2021 and has held it in 5 quarters since. The position peaked at $306K in Q2 2021. 1,191 funds tracked by Wall St. Rank hold CTVA as of Q2 2022.

  • Exane Derivatives held 12 shares of Corteva worth $650 as of Q2 2022.
  • Exane Derivatives sold 2,725 Corteva shares in Q2 2022, an estimated $158K.
  • Corteva made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #548 holding.
  • Exane Derivatives first reported a position in Corteva in Q2 2021 and has held it in 5 quarters since.
  • Exane Derivatives's Corteva position peaked at $306K in Q2 2021.
  • 1,191 funds tracked by Wall St. Rank held Corteva as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.